Effect of Unani medicine Habb-e-Hilteet in Zu‘f al-IshtihÄ’ (Anorexia)

Phase 2

Recruiting

• Conditions: Anorexia, Zu‘f al-IshtihÄ’ (Anorexia),

• Registration Number: CTRI/2018/12/016577
• Lead Sponsor: Central Council for Research in Unani Medicine New Delhi

Brief Summary

This study is designed as a multicentric open trial in patients with **Zu‘f al-IshtihÄ’ (Anorexia)** After screening, Patients will be enrolled if they satisfy inclusion and exclusion criteria.  The patients will be assessed clinically on Baseline, 7th & 14th day of treatment.  This includes subjective assessment of general well being and physical examination . The total duration of treatment will be fourteen days. Laboratory parameters for safety assessment will be conducted at baseline and on completion of the protocol therapy.

Compositionof *Habb-e-Hilteet*(NFUM-I, Page 15)

| | | | |

| --- | --- | --- | --- |

|**S. No.**

**Ingredients**

**Botanical / English Name**

**Quantity**

|1.

Hilteet

*Ferula foetida*

1 Part

|2.

Zanjabeel

*Zingiber officianale*

1 Part

|3.

Tankar Biryan

Sodium Borate/ Borax (Roasted)

1 Part

|4.

Namak-e-Sang

Rock salt

1 Part

Detailed Description

Not available

Study Timeline

• Study Start: 2016-02-03
• Last Update Posted: 2018-04-12

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• Patients of any sex in the age group 19-65 years 2.
• Patients having Zu‘f al-IshtihÄ’ (Anorexia).

Exclusion Criteria

• Patients having Anorexia nervosa 2.
• Patients having any systemic disease, chronic debilitating disease, T.B., Diabetes Mellitus etc.
• Known cases of Hepatic, Renal or Cardiac Ailments 4.
• History of hypersensitivity to study drug or any of its ingredients.
• History of addiction (Alcohol, Drugs) 6.
• Pregnant and lactating women.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement in signs and symptoms of Zu‘f al-IshtihÄ’ (Anorexia)	2 weeks

Secondary Outcome Measures

Name	Time	Method
Haematological and biochemical assessment for safety assessment	At baseline and end of treatment ie 2 weeks

Trial Locations

Locations (2)

Clinical Research Unit (CRU); 🇮🇳 Bangalore, KARNATAKA, India

Regional Research Institute of Unani Medicine; 🇮🇳 South, DELHI, India

Clinical Research Unit (CRU)

🇮🇳Bangalore, KARNATAKA, India

Dr Najeebul Hassan

Principal investigator

9886704083

crubangalore2000@yahoo.com